Valneva and BliNK Therapeutics confirm launch and funding of BliNK Biomedical

European biotechnology company Valneva SE ("Valneva") and UK company BliNK Therapeutics Ltd ("BliNK Therapeutics") announced today the closing of the transaction creating BliNK Biomedical SAS, a private company specialised in the discovery of innovative monoclonal antibodies. 

  • 20 January 2015

The new company is owned by Valneva, Kurma Biofund I (founding investor of BliNK Therapeutics), funds managed by Idinvest Partners, Cancer Research Technology (CRT) and BliNK Therapeutics’ founders.

BliNK Therapeutics’ technology has been developed by Facundo Batista, Head of the Lymphocyte Interaction Laboratory at Cancer Research UK's London Research Institute.

Related content

CRT opens Drug Discovery Laboratory in Cambridge

Cancer Research Technology Ltd (CRT), the specialist oncology development and commercialisation company, has today announced the opening of a drug discovery laboratory in Cambridge, adding to Cancer Research UK’s strong presence in the region.